GLP1R and obesity disorder: In another randomized controlled trial, the dual GLP-1/glucagon receptor agonist JNJ-64565111 (efinopegdutide) was compared at doses of 5.0 mg, 7.4 mg, or 10.0 mg to placebo for 12 wk in 195 subjects with type 2 diabetes mellitus (A1c 6.5%–9.5%), and obesity (BMI 35–50 kg/m2).